ReviewMedicine2025
Multimodality treatment approach in a patient with EGFR-mutated NSCLC and leptomeningeal metastases: A case report and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
rationaleLeptomeningeal metastases in pulmonary adenocarcinoma patients carrying epidermal growth factor receptor mutations present a critical therapeutic dilemma. However, there is no established standard therapy following drug resistance. Novel treatment modalities are urgently needed. PATIENT CONCERNS: We report a 62-year-old nonsmoking man who presented with multiple bilateral pulmonary nodules and underwent left lower lobectomy in October 2012. DIAGNOSIS: Pathological examination confirmed poorly differentiated adenocarcinoma with neuroendocrine differentiation, classified as clinical stage IV.
interventionsThe patient was initially treated with oral osimertinib; however, resistance developed after 6 months. Genetic analysis revealed an epidermal growth factor receptor exon 21 mutation. After a comprehensive treatment plan that included targeted therapy, radiotherapy, chemotherapy, and concurrent therapies. The patient achieved a total survival time of 28 months following the diagnosis of leptomeningeal metastases. OUTCOMES: The multimodality treatment method described in this case, incorporating whole-brain radiotherapy, intrathecal chemotherapy (dose escalation), and concurrent therapies, prolonged the patient's survival. LESSONS: Integrating a multimodal treatment plan that includes whole-brain radiotherapy and intrathecal administration of pemetrexed disodium could offer a promising treatment option for lung cancer patients with leptomeningeal metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.